Primary Mediastinal (Thymic) Large B-Cell Lymphoma and Classical Hodgkin Lymphoma: A Rare Case of Synchronous Lymphoid Tumors

Combined lymphoproliferative diseases always present rare and difficult-to-interpret clinical and immunomorphological situations. There are no uniform standards either for diagnosis nor for treatment of such diseases. The present paper reports a rare case of synchronous primary mediastinal (thymic) large B-cell lymphoma in a female patient with a big tumor mass in the anterior superior mediastinum and classical Hodgkin lymphoma with bone and bone marrow involvements. Combined malignancy was diagnosed after the immunomorphological analysis of the voluminous mediastinal lesion, vertebra L3, and bone marrow which had been carried out in two reference pathology laboratories. The patient received 6 chemotherapy ЕРСН-BV-R cycles (etoposide, prednisolone, cyclophosphamide, doxorubicin, and rituximab with prolonged infusion of chemotherapeutic agents replacing vincristine by brentuximab vedotin). The therapy proved to be highly effective with acceptable toxicity profile. Complete remission was confirmed by positron emission tomography and histological analysis of the bone marrow.

• Leonid Aleksandrovich Kramynin NN Petrov National Medical Cancer Research Center, 68 Leningradskaya ul., pos. Pesochnyi, Saint Petersburg, Russian Federation, 197758 https://orcid.org/0000-0003-4542-8353 (unauthenticated)
• S.S. Elkhova NN Petrov National Medical Cancer Research Center, 68 Leningradskaya ul., pos. Pesochnyi, Saint Petersburg, Russian Federation, 197758 https://orcid.org/0000-0002-1691-0549 (unauthenticated)
• A.G. Kolgotina NN Petrov National Medical Cancer Research Center, 68 Leningradskaya ul., pos. Pesochnyi, Saint Petersburg, Russian Federation, 197758 https://orcid.org/0009-0001-2174-9083 (unauthenticated)
• L.V. Filatova NN Petrov National Medical Cancer Research Center, 68 Leningradskaya ul., pos. Pesochnyi, Saint Petersburg, Russian Federation, 197758 https://orcid.org/0000-0002-0728-4582 (unauthenticated)
• I.S. Zyuzgin NN Petrov National Medical Cancer Research Center, 68 Leningradskaya ul., pos. Pesochnyi, Saint Petersburg, Russian Federation, 197758 https://orcid.org/0000-0001-9597-4593 (unauthenticated)
• A.L. Muravtseva NN Petrov National Medical Cancer Research Center, 68 Leningradskaya ul., pos. Pesochnyi, Saint Petersburg, Russian Federation, 197758 https://orcid.org/0000-0002-4221-4248 (unauthenticated)
• R.V. Grozov VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341 https://orcid.org/0000-0001-8016-7692 (unauthenticated)

1. Alduaij W, Hilton LK, Al Moosawi M, et al. Concurrent Composite Lymphomas Collectively Bearing Three Diagnostic Entities of Shared Clonal Origin. Hemasphere. 2022;6(4):e705. doi: 10.1097/HS9.0000000000000705. DOI: https://doi.org/10.1097/HS9.0000000000000705
2. Ioachim HL, Medeiros LJ. Composite lymphomas. In: Ioachim’s Lymph Node Pathology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2009. рр. 452–9.
3. Küppers R, Dührsen U, Hansmann ML. Pathogenesis, diagnosis, and treatment of composite lymphomas. Lancet Oncol. 2014;15(10):e435–e446. doi: 10.1016/S1470-2045(14)70153-6. DOI: https://doi.org/10.1016/S1470-2045(14)70153-6
4. Jaffe ES, Zarate-Osorno A, Kingma DW, et al. The interrelationship between Hodgkin’s disease and non-Hodgkin’s lymphomas. Ann Oncol. 1994;5(Suppl 1):7–11. doi: 10.1093/annonc/5.suppl_1.s7. DOI: https://doi.org/10.1093/annonc/5.suppl_1.S7
5. Traverse-Glehen A, Pittaluga S, Gaulard P, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin’s lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005;29(11):1411–21. doi: 10.1097/01.pas.0000180856.74572.73 DOI: https://doi.org/10.1097/01.pas.0000180856.74572.73
6. Hoeller S, Copie-Bergman C. Grey zone lymphomas: lymphomas with intermediate features. Adv Hematol. 2012;2012:460801. doi: 10.1155/2012/460801. DOI: https://doi.org/10.1155/2012/460801
7. Burke JS. Hodgkin lymphoma: histopathology and differential diagnosis. In: Orazi A, Foucar K, Knowles DM, Weiss LM, eds. Knowles’s neoplastic hematopathology. 3 ed. Philadelphia: Lippincott, Williams & Wilkins; 2014. рр. 354–84.
8. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102(12):3871–9. doi: 10.1182/blood-2003-06-1841. DOI: https://doi.org/10.1182/blood-2003-06-1841
9. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851–62. doi: 10.1084/jem.20031074. DOI: https://doi.org/10.1084/jem.20031074
10. Khan U, Hadid T, Ibrar W, et al. Composite Lymphoma: Opposite Ends of Spectrum Meet. J Clin Med Res. 2017;9(3):213–5. doi: 10.14740/jocmr2929w. DOI: https://doi.org/10.14740/jocmr2929w
11. Aussedat G, Traverse-Glehen A, Stamatoullas A, et al. Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases. Br J Haematol. 2020;189(2):244–56. doi: 10.1111/bjh.16331. DOI: https://doi.org/10.1111/bjh.16331
12. Liu Z, Liu C, Guo W, et al. Clinical analysis of 152 cases of multiple primary malignant tumors in 15,398 patients with malignant tumors. PLoS One. 2015;10(5):e0125754. doi: 10.1371/journal.pone.0125754. DOI: https://doi.org/10.1371/journal.pone.0125754
13. Kim H, Dorfman RF. Morphological studies of 84 untreated patients subjected to laparotomy for the staging of non-Hodgkin’s lymphomas. Cancer. 1974;33(3):657–74. doi: 10.1002/1097-0142(197403)33:3<657::aid-cncr2820330311>3.0.co;2-d. DOI: https://doi.org/10.1002/1097-0142(197403)33:3<657::AID-CNCR2820330311>3.0.CO;2-D
14. Tucci A, Motta M, Ungari M, et al. The development of more than one histologic type of lymphoma in the same patient is frequent and confers a worse prognosis. Haematologica. 2005;90(3):348–52.
15. WHO Classification of Tumours Editorial Board. Haematolymphoid Tumours. WHO Classification of Tumours, 5th ed. Lyon: IARC Press; 2024.
16. Zhang C, Yi Y, Chen C, et al. Discordant lymphoma consisting of mediastinal large B-cell lymphoma and nodular sclerosis Hodgkin lymphoma in the right supraclavicular lymph nodes: a case report. Diagn Pathol. 2015;10:215. doi: 10.1186/s13000-015-0450-6. DOI: https://doi.org/10.1186/s13000-015-0450-6
17. Oka K, Nagayama R, Iijima S, et al. Epstein-Barr virus-associated lymphoproliferative disorder presenting with classical Hodgkin lymphoma and developing as peripheral T-cell lymphoma 9 years later: a case report of composite lymphoma. Pathol Int. 2011;61(12):752–5. doi: 10.1111/j.1440-1827.2011.02723.x. DOI: https://doi.org/10.1111/j.1440-1827.2011.02723.x
18. Reed D, Middlemas E, Gertsen E, Lamb MR. Discordant B- and T-cell non-Hodgkin’s lymphoma: case report and review of literature. Tenn Med. 2013;106(10):35–7.
19. Payne K, Wright P, Grant JW, et al. BIOMED-2 PCR assays for IGK gene rearrangements are essential for B-cell clonality analysis in follicular lymphoma. Br J Haematol. 2011;155(1):84–92. doi: 10.1111/j.1365-2141.2011.08803.x. DOI: https://doi.org/10.1111/j.1365-2141.2011.08803.x
20. Leithäuser F, Bäuerle M, Huynh MQ, Möller P. Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphoma. Blood. 2001;98(9):2762–70. doi: 10.1182/blood.v98.9.2762. DOI: https://doi.org/10.1182/blood.V98.9.2762
21. Мангасарова Я.К., Сидорова Ю.В., Магомедова А.У. Реаранжировки генов иммуноглобулинов в опухолевых клетках у пациентов c первичной медиастинальной (тимической) В-крупноклеточной лимфомой. Клиническая онкогематология. 2019;12(3):271–7. doi: 10.21320/2500-2139-2019-12-3-271-277. [Mangasarova Ya.K., Sidorova Yu.V., Magomedova A.U. Rearrangements of Immunoglobulin Genes in Tumor Cells of Patients with Primary Mediastinal (Thymic) Large B-Cell Lymphoma. Clinical oncohematology. 2019;12(3):271–7. doi: 10.21320/2500-2139-2019-12-3-271-277. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2019-12-3-271-277
22. Tiacci E, Döring C, Brune V, et al. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood. 2012;120(23):4609–20. doi: 10.1182/blood-2012-05-428896. DOI: https://doi.org/10.1182/blood-2012-05-428896
23. Mata E, Fernández S, Astudillo A, et al. Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma. Blood Cancer J. 2019;9(3):34. doi: 10.1038/s41408-019-0195-7. DOI: https://doi.org/10.1038/s41408-019-0195-7
24. NCCN Guidelines Version 1.2025. Primary Mediastinal Large B-Cell Lymphoma. Available from: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf (accessed 03.02.2025).
25. NCCN Guidelines Version 1.2025. Hodgkin Lymphoma (Age 18–60 years). Available from: https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf (accessed 03.02.2025).
26. Zinzani PL, Santoro A, Gritti G, et al. Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. J Clin Oncol. 2019;37(33):3081–9. doi: 10.1200/JCO.19.01492. DOI: https://doi.org/10.1200/JCO.19.01492
27. Svoboda J, Bair SM, Landsburg DJ, et al. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica. 2021;106(6):1705–13. doi: 10.3324/haematol.2019.238675. DOI: https://doi.org/10.3324/haematol.2019.238675